My Hero Academia comes to an end with a major time skip, revealing what lies in store for the Class 1-A members.
Stocktwits on MSN
CRBP stock surged 36% pre-market – what did its obesity treatment drug study reveal?
CRB-913 is an oral small-molecule inverse agonist targeting the CB1 receptor, a known pathway for weight loss. ・The study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback